About: GeoVax

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: GeoVax Goto Sponge NotDistinct Permalink

An Entity of Type : yago:SocialGroup107950920, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/4UYSViyJbh

GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against many serious human diseases for which there are significant unmet medical needs. GeoVax’ novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated. In human clinical trials of the company’s HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response.

Attributes	Values
rdf:type	company yago:WikicatBiotechnologyCompaniesOfTheUnitedStates yago:WikicatCompaniesBasedInAtlanta,Georgia yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity yago:SocialGroup107950920
rdfs:label	GeoVax (en)
rdfs:comment	GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against many serious human diseases for which there are significant unmet medical needs. GeoVax’ novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated. In human clinical trials of the company’s HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response. (en)
dct:subject	Biotechnology companies of the United States Companies based in Atlanta 2001 establishments in Georgia (U.S. state) HIV vaccine research Biotechnology companies established in 2001
Wikipage page ID	13430526 (xsd:integer)
Wikipage revision ID	1107002588 (xsd:integer)
Link from a Wikipage to another Wikipage	DNA Vaccine Biotechnology companies of the United States Companies based in Atlanta Emory University Genes Modified vaccinia Ankara Antibody Clinical trial Zika fever COVID-19 HIV HIV Vaccine Trials Network Lassa fever AIDS 2001 establishments in Georgia (U.S. state) HIV-1 Atlanta, Georgia HIV vaccine research Biotechnology companies established in 2001 Biotechnology Ebola Marburg HVTN National Institute of Allergy and Infectious Diseases National Institutes of Health Immune Virus-like particle Diseases NASDAQ Capital Market T cell Therapeutic Vaccinated Preclinical
Link from a Wikipage to an external page	http://www.geovax.com/ http://wn.com/GeoVax https://web.archive.org/web/20110703043600/http:/www.geovax.com/newsroom/corporate_news.php https://web.archive.org/web/20110711085627/http:/www.geovax.com/technologyandproducts/publications.php
sameAs	GeoVax GeoVax GeoVax GeoVax
dbp:wikiPageUsesTemplate	dbt:Citation_needed dbt:Reflist dbt:Short_description
has abstract	GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against many serious human diseases for which there are significant unmet medical needs. GeoVax’ novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated. In human clinical trials of the company’s HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response. (en)
gold:hypernym	Company
skos:closeMatch	http://www.grid.ac/institutes/grid.434905.f
prov:wasDerivedFrom	wikipedia-en:GeoVax?oldid=1107002588&ns=0
page length (characters) of wiki page	13831 (xsd:nonNegativeInteger)
foaf:isPrimaryTopicOf	wikipedia-en:GeoVax
is Link from a Wikipage to another Wikipage of	Sudan ebolavirus
is foaf:primaryTopic of	wikipedia-en:GeoVax

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3331 as of Sep 2 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software